Cargando…
Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/ https://www.ncbi.nlm.nih.gov/pubmed/36079789 http://dx.doi.org/10.3390/nu14173531 |
_version_ | 1784786583209115648 |
---|---|
author | Hata, Shinnosuke Okamura, Takuro Kobayashi, Ayaka Bamba, Ryo Miyoshi, Tomoki Nakajima, Hanako Kitagawa, Nobuko Hashimoto, Yoshitaka Majima, Saori Senmaru, Takafumi Okada, Hiroshi Ushigome, Emi Nakanishi, Naoko Takakuwa, Hiroshi Sasano, Ryoichi Hamaguchi, Masahide Fukui, Michiaki |
author_facet | Hata, Shinnosuke Okamura, Takuro Kobayashi, Ayaka Bamba, Ryo Miyoshi, Tomoki Nakajima, Hanako Kitagawa, Nobuko Hashimoto, Yoshitaka Majima, Saori Senmaru, Takafumi Okada, Hiroshi Ushigome, Emi Nakanishi, Naoko Takakuwa, Hiroshi Sasano, Ryoichi Hamaguchi, Masahide Fukui, Michiaki |
author_sort | Hata, Shinnosuke |
collection | PubMed |
description | In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-old male db/db mice were fed a normal diet (Ctrl), LCD, and normal diet with 0.01% w/w luseogliflozin (SGLT2i) for eight weeks. Skeletal muscle mass and grip strength decreased in the LCD group mice compared to those in the control group, while they increased in the SGLT2i group mice. The amino acid content in the liver, skeletal muscle, and serum were lower in the LCD group than those in the Ctrl group but increased in the SGLT2i group mice. Short-chain fatty acids in rectal feces were lower in the LCD group mice than those in the Ctrl group, whereas they were higher in the SGLT2i group mice. The abundance of Gammaproteobacteria, Enterobacteriaceae, Escherichia, Enterobacterales, and Bacteroides caccae species increased in the LCD group compared to the other two groups, whereas the abundance of Syntrophothermus lipocalidus, Syntrophomonadaceae family, Parabacteroidesdistasonis distasonis, and the genus Anaerotignum increased in the SGLT2i group. Luseogliflozin could prevent sarcopenic obesity by improving amino acid metabolism. |
format | Online Article Text |
id | pubmed-9459736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94597362022-09-10 Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice Hata, Shinnosuke Okamura, Takuro Kobayashi, Ayaka Bamba, Ryo Miyoshi, Tomoki Nakajima, Hanako Kitagawa, Nobuko Hashimoto, Yoshitaka Majima, Saori Senmaru, Takafumi Okada, Hiroshi Ushigome, Emi Nakanishi, Naoko Takakuwa, Hiroshi Sasano, Ryoichi Hamaguchi, Masahide Fukui, Michiaki Nutrients Article In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-old male db/db mice were fed a normal diet (Ctrl), LCD, and normal diet with 0.01% w/w luseogliflozin (SGLT2i) for eight weeks. Skeletal muscle mass and grip strength decreased in the LCD group mice compared to those in the control group, while they increased in the SGLT2i group mice. The amino acid content in the liver, skeletal muscle, and serum were lower in the LCD group than those in the Ctrl group but increased in the SGLT2i group mice. Short-chain fatty acids in rectal feces were lower in the LCD group mice than those in the Ctrl group, whereas they were higher in the SGLT2i group mice. The abundance of Gammaproteobacteria, Enterobacteriaceae, Escherichia, Enterobacterales, and Bacteroides caccae species increased in the LCD group compared to the other two groups, whereas the abundance of Syntrophothermus lipocalidus, Syntrophomonadaceae family, Parabacteroidesdistasonis distasonis, and the genus Anaerotignum increased in the SGLT2i group. Luseogliflozin could prevent sarcopenic obesity by improving amino acid metabolism. MDPI 2022-08-27 /pmc/articles/PMC9459736/ /pubmed/36079789 http://dx.doi.org/10.3390/nu14173531 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hata, Shinnosuke Okamura, Takuro Kobayashi, Ayaka Bamba, Ryo Miyoshi, Tomoki Nakajima, Hanako Kitagawa, Nobuko Hashimoto, Yoshitaka Majima, Saori Senmaru, Takafumi Okada, Hiroshi Ushigome, Emi Nakanishi, Naoko Takakuwa, Hiroshi Sasano, Ryoichi Hamaguchi, Masahide Fukui, Michiaki Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title | Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title_full | Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title_fullStr | Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title_full_unstemmed | Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title_short | Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice |
title_sort | gut microbiota changes by an sglt2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/ https://www.ncbi.nlm.nih.gov/pubmed/36079789 http://dx.doi.org/10.3390/nu14173531 |
work_keys_str_mv | AT hatashinnosuke gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT okamuratakuro gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT kobayashiayaka gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT bambaryo gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT miyoshitomoki gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT nakajimahanako gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT kitagawanobuko gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT hashimotoyoshitaka gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT majimasaori gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT senmarutakafumi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT okadahiroshi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT ushigomeemi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT nakanishinaoko gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT takakuwahiroshi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT sasanoryoichi gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT hamaguchimasahide gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice AT fukuimichiaki gutmicrobiotachangesbyansglt2inhibitorluseogliflozinaltersmetabolitescomparedwiththoseinalowcarbohydratedietindbdbmice |